From a molecular pharmacy viewpoint, Relafen 750 (naproxen sodium) embodies a compelling case study in noncopyrightal anti-inflammatory agent action. Its process of alleviating inflammation and soreness copyrights primarily on the inhibition of cyclooxygenase (COX) catalysts, specifically COX-1 and COX-2. Examining the selective nuances of this int